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CARBAPENEM-RESISTANT 
ENTEROBACTERIACEAE 
THREAT LEVEL URGENT
13,100
Estimated cases 
in hospitalized 
patients in 2017 
1,100
Estimated 
deaths in 2017 
$130M
Estimated attributable 
healthcare costs in 2017
Carbapenem-resistant Enterobacteriaceae (CRE) are a major concern for patients in healthcare facilities. Some 
bacteria in this family are resistant to nearly all antibiotics, leaving more toxic or less effective treatment options.
WHAT YOU NEED TO KNOW
 ■ Patients who require devices (e.g., catheters) and 
patients taking long courses of some antibiotics are 
most at risk for CRE infections. 
 ■ CRE can carry mobile genetic elements that are easily 
shared between bacteria. Approximately 30% of 
CRE carry a mobile genetic element that can make 
an enzyme, which makes carbapenem antibiotics 
ineffective and rapidly spreads resistance that destroys 
these important drugs. 
 ■ Preventing CRE infections and containing the spread of 
carbapenem resistance is important to protect people. 
CASES OVER TIME
Containment strategies have prevented further spread of some 
types of CRE in the United States, but continued action is needed.
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STOPPING CRE 
CDC developed a robust system for detecting and 
responding to carbapenemase-producing CRE (CP-
CRE) in the United States. In 2016, CDC established 
the Antibiotic Resistance Laboratory Network (AR 
Lab Network). Through the network, labs in 50 states, 
many major cities, and Puerto Rico provide clinical 
laboratories access to advanced detection capacities to 
identify patients with CP-CRE infections. The AR Lab 
Network also provides testing to screen people at risk 
for CP-CRE to help slow or stop its spread. 
Patients with CP-CRE may have gone unrecognized 
before the AR Lab Network. When CP-CRE is 
identified now, health departments and healthcare 
facilities can take action to contain its spread, such as 
having healthcare providers wear gowns and gloves 
when providing care. This new national public health 
infrastructure means rapid action is taken to stop 
spread when even one CP-CRE case is identified.
CDC’S AR LAB NETWORK 
To avoid spread seen in the past, CDC funded infrastructure 
to rapidly detect and respond to future unusual resistance 
threats. Laboratories nationwide work together to fight 
antibiotic resistance.
CLINICAL LABS
Collect and submit patient samples for testing at public health 
department and regional labs
PUBLIC HEALTH DEPARTMENT LABS
Characterize patient samples for species type, carbapenemase 
production, and resistance profiles
7 REGIONAL LABS AND NATIONAL TB CENTER
Detect antibiotic resistance, track changes in resistance, and 
identify outbreaks
CDC
Coordinates the network, provides technical expertise, and 
supports outbreak responses
ONLINE RESOURCES
About CRE in Healthcare Settings
www.cdc.gov/hai/organisms/cre
CDC Vital Signs: Containing Unusual Resistance 
www.cdc.gov/vitalsigns/containing-unusual-resistance
This fact sheet is part of CDC’s 2019 Antibiotic Resistance Threats Report.  
The full report, including data sources, is available at www.cdc.gov/DrugResistance/Biggest-Threats.html.
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